Pharming Group (ENXTAM:PHARM) - Hisse Senedi Fiyatı, Haberler ve Analizler

PHARM Stoklara Genel Bakış

PHARM temel anali̇z
Kar Tanesi Skoru
Değerleme	6/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 91.2% daha düşük bir oranda işlem görüyor

Kazançların yılda 73.16% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Analistler hisse senedi fiyatının 151.4% oranında artacağı konusunda hemfikir

Risk Analizi

Son 3 ayda dalgalı hisse senedi fiyatı

Pharming Group N.V. Rakipler

Galapagos

ENXTAM:GLPG

€1.7b

Medy-Tox

KOSDAQ:A086900

₩867.0b

Beijing Kawin Technology Share-Holding

SHSE:688687

CN¥4.3b

Basilea Pharmaceutica

SWX:BSLN

CHF 500.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Pharming Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€0.72
52 Haftanın En Yüksek Seviyesi	€1.22
52 Haftanın En Düşük Seviyesi	€0.65
Beta	0.81
11 Aylık Değişim	-10.95%
3 Aylık Değişim	1.92%
1 Yıllık Değişim	-32.07%
33 Yıllık Değişim	0.084%
5 Yıllık Değişim	-49.68%
Halka arzdan bu yana değişim	-99.24%

Son Haberler & Güncellemeler

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12

Hissedar Getirileri

	PHARM	NL Biotechs	NL Pazar
7D	0.4%	3.8%	0.9%
1Y	-32.1%	6.0%	7.6%

Getiri vs. Endüstri: PHARM geçen yıl % 6 oranında getiri sağlayan Dutch Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: PHARM geçen yıl % 7.6 oranında getiri sağlayan Dutch Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is PHARM's price volatile compared to industry and market?
PHARM volatility
PHARM Average Weekly Movement	6.9%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.0%
10% most volatile stocks in NL Market	7.2%
10% least volatile stocks in NL Market	2.2%

İstikrarlı Hisse Senedi Fiyatı: PHARM hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: PHARM 'nin haftalık oynaklığı ( 7% ) geçen yıl boyunca sabit kaldı, ancak hala Dutch hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1988	382	Simon de Vries	www.pharming.com

Bir biyofarmasötik şirketi olan Pharming Group N.V., Amerika Birleşik Devletleri, Avrupa ve uluslararası alanda nadir hastalıkların tedavisi için protein replasman tedavileri ve hassas ilaçlar geliştirmekte ve ticarileştirmektedir. Şirket, akut herediter anjiyoödemi (HAE) olan yetişkin ve ergen hastalarda akut atakların tedavisi için rekombinant bir C1 esteraz inhibitörü olan RUCONEST'i ve aktive fosfoinositid 3-kinaz delta sendromunun tedavisi için oral küçük moleküllü bir PI3K inhibitörü olan Joenja'yı (leniolisib) sunmaktadır. Ayrıca HAÖ tedavisi için araştırma amaçlı bir ex-vivo otolog hematopoetik kök hücre gen terapisi olan OTL-105'i geliştirmektedir.

Pharming Group N.V. Temel Bilgiler Özeti

Pharming Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PHARM temel i̇stati̇sti̇kler
Piyasa değeri	€485.70m
Kazançlar(TTM)	-€17.12m
Gelir(TTM)	€274.40m

1.8x

P/S Oranı

-28.4x

F/K Oranı

PHARM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PHARM gelir tablosu (TTM)
Gelir	US$285.75m
Gelir Maliyeti	US$30.30m
Brüt Kâr	US$255.44m
Diğer Giderler	US$273.26m
Kazançlar	-US$17.82m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.026
Brüt Marj	89.39%
Net Kâr Marjı	-6.24%
Borç/Özkaynak Oranı	42.3%

PHARM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PHARM Stoklara Genel Bakış

Ödüller

Risk Analizi

Pharming Group N.V. Rakipler

ENXTAM:GLPG

€1.7b

KOSDAQ:A086900

₩867.0b

SHSE:688687

CN¥4.3b

SWX:BSLN

CHF 500.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Recent updates

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Insufficient new directors

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations